Ohio Administrative Code
Title 4731 - State Medical Board
Chapter 4731-33 - Opioid Treatment
Section 4731-33-04 - Medication-assisted treatment using naltrexone
Universal Citation: OH Admin Code 4731-33-04
Current through all regulations passed and filed through September 16, 2024
(A) In addition to the requirements of paragraphs (A) to (F) of rule 4731-33-03 of the Administrative Code, the physician using naltrexone to treat opioid use disorder shall comply with all of the following requirements:
(1)
Prior to treating
a patient with naltrexone the physician shall inform the patient about the risk
of opioid overdose if the patient ceases naltrexone and then uses opioids. The
physician shall take measures to ensure that the patient is adequately
detoxified from opioids and is no longer physically dependent prior to
treatment with naltrexone.
(2)
The physician
shall use oral naltrexone only for treatment of patients who can be closely
supervised and who are highly motivated.
(a)
The dosage regime
shall strictly comply with the food and drug administration approved labeling
for naltrexone hydrochloride tablets.
(b)
The patient shall
be encouraged to have a support person administer and supervise the medication.
Examples of a support person are a family member, close friend, or
employer.
(c)
The physician shall require urine drug screens,serum
medication levels, or oral fluid drug testing at least every three months for
the first year of treatment and at least every six months
thereafter.
(d)
The physician shall incorporate relapse prevention
strategies into counseling or assure that they are addressed by a qualifed
behavioral healthcare provider, as defined in rule
4731-33-01 of the
Administrative Code, who has the education and experience to provide substance
abuse counseling.
(B) The physician may treat a patient with extended-release naltrexone for opioid dependence or for co-occuring opioid and alcohol use disorders.
(1)
The physician
should consider treatment with extended-release naltrexone for patients who
have issues with treatment adherence.
(2)
The injections
dosage shall strictly comply with the United States food and drug
administration approved labeling for extended-release
naltrexone.
(3)
The physician shall incorporate relapse prevention
strategies into counseling or assure that they are addressed by a qualified
behavioral healthcare provider, as defined in rule
4731-33-01 of the
Administrative Code, who has the education and experience to provide substance
abuse counseling.
Disclaimer: These regulations may not be the most recent version. Ohio may have more current or accurate information. We make no warranties or guarantees about the accuracy, completeness, or adequacy of the information contained on this site or the information linked to on the state site. Please check official sources.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.